Reuters logo
BRIEF-Otsuka and Mylan announce license agreement to commercialize Delamanid
August 24, 2017 / 7:49 AM / a month ago

BRIEF-Otsuka and Mylan announce license agreement to commercialize Delamanid

Aug 24 (Reuters) - Mylan Nv

* Mylan NV- Otsuka Pharmaceutical Co Ltd, co entered into license agreement between their respective subsidiaries ONPG and Mylan Pharmaceuticals Private Limited

* Mylan NV- license deal to commercialize Delamanid for treatment of adults with pulmonary multidrug-resistant tuberculosis in low & middle-income countries

* Mylan NV- under terms of the agreement, Mylan has been granted license by Otsuka to prioritize access to Deltyba™ in South Africa and India Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below